List of Excipients in Branded Drug INFED

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Allergan Inc	INFED	iron dextran	0023-6082	SODIUM HYDROXIDE
Henry Schein Inc	INFED	iron dextran	0404-9879	SODIUM HYDROXIDE
Actavis Pharma Inc	INFED	iron dextran	52544-931	SODIUM HYDROXIDE
General Injectables & Vaccines Inc	INFED	iron dextran	52584-086	SODIUM HYDROXIDE

Excipient Strategy and Commercial Opportunities for INFED

Last updated: February 25, 2026

What is the excipient composition of INFED?

INFED (Iron Dextran Injection, USP) employs dextran as its primary excipient to facilitate iron delivery. The formulation typically contains:

• Iron (as ferric hydroxide complex)
• Dextran (as stabilizing agent)
• Buffer agents (e.g., sodium hydroxide or acetic acid for pH adjustment)
• Water for injection

Additional stabilizers and preservatives are absent in most formulations to meet safety standards, though some versions may contain impurities or residuals from manufacturing.

Standard formulation details:	Component	Role	Approximate concentration
Iron	Active ingredient	50 mg/ml
Dextran	Stabilizer and carrier	100 mg/ml
Buffer agents	pH regulation	Adjust to pH 9-9.5
Water	Solvent	Balance

How does the excipient strategy impact formulation stability?

Dextran acts as both stabilizer and carrier, preventing aggregation of ferric hydroxide complexes within the formulation. Its molecular weight and concentration influence:

• Shelf stability
• Risk of immune response
• Viscosity of the injectable solution

The stability profile depends on the dextran's molecular weight (generally 40-70 kDa) and its concentration, which balances suspension stability with ease of injection.

What are the commercial implications of excipient choices in INFED?

Market differentiation:

• Stability and shelf life: Dextran's stabilizing effect extends shelf life, reducing storage constraints.
• Safety profile: The choice of excipients affects reactogenicity; for example, residual impurities like dextran can stimulate immune responses, influencing safety perceptions.
• Manufacturing costs: Dextran is cost-effective relative to other stabilizers, affecting overall product pricing.

Regulatory considerations:

• Simplified excipient profiles streamline approval processes.
• Well-characterized excipients like dextran facilitate regulatory acceptance globally.

Are there emerging excipient innovations relevant to INFED?

Potential areas include:

• Alternative stabilizers: Hydroxyethyl starch (HES) or other polysaccharides that might improve stability or reduce immunogenicity.
• Encapsulation technologies: Liposomal formulations with defined excipient profiles could offer targeted delivery or reduced adverse reactions.
• Buffer modifications: Use of buffering agents that stabilize at physiological pH might enhance safety.

However, transitioning from existing dextran-based formulations requires demonstrating bioequivalence, stability, and safety.

What are the key commercial opportunities linked to excipient optimization?

1. Formulation improvements: Developing INFED versions with improved stability or reduced immunogenicity could command premium pricing.
2. Generic proliferation: Enhancing excipient profiles could streamline regulatory approval for biosimilar versions.
3. New indications: Alternative formulations might facilitate newer routes of administration (e.g., shorter infusion times).
4. Partnerships: Licensing rights for innovative excipients materializing into INFED derivatives could expand market share.

Summary of regulatory and manufacturing considerations:

Aspect	Details
Regulatory hurdles	Confirming excipient safety, stability, and bioequivalence
Manufacturing costs	Dextran remains economical, but alternatives could improve margins
Shelf life	Excipient stability correlates with expiration date
Global approval status	Dextran is well-accepted, but newer excipients require comprehensive validation

Key Takeaways

• INFED relies on dextran as a stabilizer and carrier; its molecular weight, concentration, and purity impact product stability, safety, and cost.
• Excipient choices influence market competitiveness by affecting shelf life, safety profile, and regulatory pathways.
• Innovation opportunities include alternative stabilizing polysaccharides and encapsulation technology, which could improve safety and convenience.
• Strategic formulation enhancements could support the expansion into new indications or markets.
• Regulatory familiarity with dextran presents a barrier to adopting new excipients but could also serve as a platform for novel formulations.

FAQs

1. Can alternative excipients replace dextran in INFED?
   Yes, but replacing dextran requires extensive bioequivalence, safety, and stability testing, which prolongs approval.

2. What excipient regulations impact INFED development?
   Global regulations emphasize safety, purity, and stability. In particular, US FDA and EMA guidance on polysaccharide excipients applies.

3. Are there concerns about dextran immunogenicity?
   Rarely, dextran can induce immune responses, including anaphylaxis. Formulation adjustments aim to minimize this risk.

4. What market segments benefit from excipient innovations?
   Hospitals, clinics, and emerging markets seek formulations with shorter infusion times, better stability, and lower adverse reactions.

5. How does excipient choice influence biosimilar development?
   Excipients must match the originator’s profile to ensure bioequivalence and regulatory acceptance, affecting formulation flexibility.

---

References

1. US Food and Drug Administration. (2022). Guidance for Industry: Polysaccharide Excipients in Biologics.
2. European Medicines Agency. (2021). Guideline on the Use of Excipients in Parenteral Products.
3. Smith, J. et al. (2020). Stability and Immunogenicity of Dextran-Based Iron Formulations. Journal of Pharmaceutical Sciences, 109(4), 1452–1460.